CA
LGND icon

Cynosure Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Cynosure Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,682
Closed -$347K – 115
2018
Q2 		$347K Hold
2,682
– – 0.09% 167
2018
Q1 		$276K Buy
+2,682
New +$265K 0.07% 192

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cynosure Advisors's LGND Position: Q3 2018 in Review

Cynosure Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 2,682 shares — an estimated $347K sold.

Cynosure Advisors first reported a position in LGND in Q1 2018 and held it in 2 quarters. The position peaked at $347K in Q2 2018. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

  • Cynosure Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cynosure Advisors sold 2,682 Ligand Pharmaceuticals shares in Q3 2018, an estimated $347K.
  • Cynosure Advisors first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Cynosure Advisors's Ligand Pharmaceuticals position peaked at $347K in Q2 2018.
  • 385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on Cynosure Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.